Purpose: Three previous articles provided rationale, methods, and several forms of validity support for a diagnostic marker of childhood apraxia of speech (CAS), termed the pause marker (PM). Goals of the present article were to assess the validity and stability of the PM Index (PMI) to scale CAS severity. Method: PM scores and speech, prosody, and voice precision-stability data were obtained for participants with CAS in idiopathic, neurogenetic, and complex neurodevelopmental disorders; adult-onset apraxia of speech consequent to stroke and primary progressive apraxia; and idiopathic speech delay. Three studies were completed including criterion and concurrent validity studies of the PMI and a temporal stability study of the PMI using retrospective case studies. Results: PM scores were significantly correlated with other signs of CAS precision and stability. The best fit of the distribution of PM scores to index CAS severity was obtained by dividing scores into 4 ordinal severity classifications: mild, mild-moderate, moderate-severe, and severe. Severity findings for the 4 classifications and retrospective longitudinal findings from 8 participants with CAS supported the validity and stability of the PMI. Conclusion: Findings support research and clinical use of the PMI to scale the severity of CAS.A four-article series (Shriberg et al., 2017a(Shriberg et al., , 2017b(Shriberg et al., , 2017c, and the present article) to develop and assess the theoretical and clinical utility of a singlesign, behavioral marker of childhood apraxia of speech (CAS) poses the following three questions:
1.Do findings from construct and criterion validity studies support the diagnostic accuracy of a behavioral marker, the pause marker (PM), to discriminate CAS from speech delay (SD)?2. Do findings from the PM and other measures support the hypothesis of core representational and transcoding deficits in CAS, and is the PM theoretically coherent with those deficits?3. Do findings from cross-sectional and retrospective longitudinal case studies support an ordinal scale of PM scores, the Pause Marker Index (PMI), to quantify the severity of CAS for research and clinical applications?The short-term goal of the PM is to provide a behavioral marker of CAS for research and clinical practice. A longer term goal of the PM is to provide quantitative inclusionary and exclusionary criteria to identify participants who are true positive for CAS in studies to identify and validate a biomarker of CAS. The present article addresses both goals. As proposed in the first article in this series (PM I; Shriberg et al., 2017a, Table 1), a highly valued attribute of diagnostic markers is generality, that is, a marker has research and clinical utility beyond identifying presence or absence of a disorder. In the present context, a behavioral marker of CAS has research and clinical generality when in addition to being diagnostically sensitive to and specific for a prior, active, and/or future disorder, it also quantifies the severity of the disorder. The three...